AstraZeneca PLC (AZN) operating KPIs
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca beyfortus (nirsevimab — direct product sales) — Worldwide product sales ($M) ($M)
Form 6-K Quarterly & Form 20-F Product Sales by Medicine & Region Tables
Latest, Q2 2026
47
Period ended Jun 30, 2026
Change on a year earlier
-52.0%
98 in Q2 2025
History
13 quarters
Since Q2 2023
Sources
13
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Beyfortus (nirsevimab — direct product sales) — Worldwide product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 47 | -52.0% | Form 6-K FY2026Q2 Earnings Release ↗ |
| Q1 2026 | Mar 31, 2026 | 24 | -20.0% | Form 6-K FY2026Q1 Earnings Release ↗ |
| Q4 2025 | Dec 31, 2025 | 59 | -54.6% | Form 6-K FY2025Q4 Earnings Release ↗ |
| Q3 2025 | Sep 30, 2025 | 94 | -29.9% | Form 6-K FY2025Q3 Earnings Release ↗ |
| Q2 2025 | Jun 30, 2025 | 98 | +250.0% | Form 6-K FY2025Q2 Earnings Release ↗ |
| Q1 2025 | Mar 31, 2025 | 30 | +15.4% | Form 6-K FY2025Q1 Earnings Release ↗ |
| Q4 2024 | Dec 31, 2024 | 130 | +140.7% | Form 6-K FY2024Q4 Earnings Release ↗ |
| Q3 2024 | Sep 30, 2024 | 134 | +168.0% | Form 6-K FY2024Q3 Earnings Release ↗ |
| Q2 2024 | Jun 30, 2024 | 28 | +1,300.0% | Form 6-K FY2024Q2 Earnings Release ↗ |
| Q1 2024 | Mar 31, 2024 | 26 | – | Form 6-K FY2024Q1 Earnings Release ↗ |
| Q4 2023 | Dec 31, 2023 | 54 | – | Form 6-K FY2023Q4 Earnings Release ↗ |
| Q3 2023 | Sep 30, 2023 | 50 | – | Form 6-K FY2023Q3 Earnings Release ↗ |
| Q2 2023 | Jun 30, 2023 | 2 | – | Form 6-K FY2023Q2 Earnings Release ↗ |
Breakdown
What makes up beyfortus (nirsevimab — direct product sales) — worldwide product sales ($m)
- Beyfortus (nirsevimab — direct product sales) — Worldwide YoY actual (%)-52.0% · Q2 2026
- Beyfortus (nirsevimab — direct product sales) — Worldwide YoY CER (%)-52.0% · Q2 2026
- Beyfortus (nirsevimab — direct product sales) — US product sales ($M)38 · Q2 2026
- Beyfortus (nirsevimab — direct product sales) — Emerging Markets product sales ($M)0 · Q2 2026
- Beyfortus (nirsevimab — direct product sales) — Europe product sales ($M)8 · Q2 2026
- Beyfortus (nirsevimab — direct product sales) — Established RoW product sales ($M)1 · Q2 2026
Cite this data
StockData. (2026). AstraZeneca Beyfortus (nirsevimab — direct product sales) — Worldwide product sales ($M) ($M), quarterly Q2 2023–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med_beyfortus_world
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.